Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety
Gb Sciences (OTCQB:GBLX) has launched new preclinical studies at the National Research Council of Canada, utilizing its AI-driven PhAROS™ platform to identify novel, plant-inspired formulations aimed at treating depression and anxiety. This marks the company's first non-cannabis formulations in preclinical testing. The formulations are based on a new combination of plant compounds, replacing potentially liver-toxic ingredients from the kava plant with safer alternatives from the Piper plant family. The studies may lead to innovative treatments for mental health disorders.
- Initiated new preclinical studies at NRC on plant-inspired formulations for depression and anxiety.
- PhAROS™ platform enables rapid identification of effective drug candidates, reducing time and costs.
- First non-cannabis formulations entering preclinical studies, marking a significant development milestone.
- Original formulation based on kava was found to have potentially liver-toxic ingredients.
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
LAS VEGAS, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical studies at the National Research Council of Canada ("NRC") through GbS' Canadian subsidiary, GbS Global Biopharma, Inc. The NRC will test GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates to treat depression and anxiety. These are the company's first non-cannabis formulations to enter preclinical studies.
The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines.
"Using AI pushes biomedical research forward past simplistic approaches to drug design because computer modeling of complex human diseases allows for the identification of suitably complex, multi-ingredient treatments," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer. "Our PhAROS™ platform yields numerous concrete, potentially-effective, plant-inspired combination drugs. This now includes formulations designed to help the millions of people around the world who are affected by depression and anxiety."
For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.
GbS' new psychotropic formulations are currently in preclinical trials at the Zebrafish Toxicology, Genomics and Neurobiology Lab at the NRC, led by Dr. Lee Ellis, Research Officer and Team Lead. The ongoing work between the NRC and Gb Sciences has produced strong and applicable data for the evaluation of its therapies, and this trial could provide novel treatment options for patients with depression and anxiety.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-based research and biopharma drug development company creating patented, disease-targeted formulations of plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc.. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' novel drug discovery platform has yielded five issued U.S. and three issued international patents, as well as 21 U.S. and 42 international patent-pending applications. In its drug development pipeline, the company has four preclinical-stage programs, and its lead Parkinson's disease therapeutic program is being prepared for a First-in-Man clinical trial. In addition to Parkinson's disease, Gb Sciences is developing therapeutics for COVID-related cytokine release syndrome (CRS), chronic pain, anxiety, depression, Mast Cell Activation Syndrome (MCAS), and heart failure. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Media Contact
Savannah Muir
savannah@newswire.com
Related Images
This content was issued through the press release distribution service at Newswire.com.
Attachment
FAQ
What are the recent developments for Gb Sciences regarding GBLX?
What technology is Gb Sciences using for their drug discovery?
What are the key benefits of the new formulations developed by Gb Sciences?
Where are the preclinical studies for Gb Sciences being conducted?
What is the potential impact of the new treatments from Gb Sciences?
